Our Team

Scientific Advisory Board

prof.dr.
L.W.M.M. Terstappen

Prof. Dr. Leon Terstappen is a Dutch scientist and a leading expert in cancer diagnostics and single-cell analysis. Following his medical degree from the University of Groningen and PhD in Biophysics at the University of Twente, he worked at Becton Dickinson in various roles and later at Immunicon, where he served as Chief Scientific Officer. He was instrumental in developing the CellSearch system, the first FDA-cleared technology for detecting circulating tumour cells (CTCs) in cancer patients. Until recently, he served as Chair of the Department of Medical Cell BioPhysics at the University of Twente, where he headed a research group in CTCs.

prof.dr.
B. Löwenberg

Prof. Dr. Bob Löwenberg is a hematologist and emeritus professor at the Erasmus Medical Center Rotterdam, where he headed the department of hematology for many years. Prof Löwenberg has won numerous awards in recognition for his major scientific and clinical achievements. He has also served as the editor-in-chief of the scientific journal Blood. He was one of the co-founders of IntroGene, which later became Crucell and was acquired by Johnson & Johnson. Furthermore, he also co-founded Frame Cancer Therapeutics, which was acquired by CureVac in 2022.





prof.dr.
J.B.A.G. Haanen

Prof. Dr. John Haanen is renowned for his work on tumour immunology and immunotherapy. After his studies in chemistry and medicine, he performed a PhD in immunology at Leiden University Medical Center. Prof. Dr. Haanen was trained as an internist and work for many years at the Netherlands Cancer Institute, both as research group leader, professor in translational immunotherapy of cancer, and as head of the Division of Medical Oncology. Internationally, has held several roles in oncology at the European Society of Medical Oncology.




prof.dr.

N.H. Stoecklein

Prof. Dr. Nikolas Stoecklein is currently appointed as Professor for Experimental Surgical Oncology at the Heinrich-Heine University, Düsseldorf. He studied medicine at the University of Hamburg and the University of California Davis. His major research interests are minimal residual cancer and early systemic disease in gastrointestinal cancers. Currently, his work focuses on CTCs and establishing workflows to analyse these rare cells comprehensively at single cell level. Prior to joining the HHU, Nikolas Stoecklein obtained post-doctoral training at the Institute of Immunology of the Ludwig-Maximilians-University Munich, Germany, in the group of Christoph Klein.

Tzu Cancer Therapeutics

Inspired by the wisdom of Sun Tzu, we aim to revolutionize cancer treatment through cutting-edge, personalized solutions that enhance patient care and outcomes.

Quick Links

Contact Us

Matrix ONE

Science Park 301 | 1098 XH

Amsterdam | The Netherlands

info@tzu.nl